200,000+ products from a single source!
sales@angenechem.com
125973-56-0 | Benzoic acid, 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]-
CAS No: 125973-56-0 Catalog No: AG000QLS MDL No:
Product Description
Catalog Number:
AG000QLS
Chemical Name:
Benzoic acid, 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]-
CAS Number:
125973-56-0
Molecular Formula:
C20H27NO3Si2
Molecular Weight:
385.6043
IUPAC Name:
4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
InChI:
InChI=1S/C20H27NO3Si2/c1-25(2,3)17-11-15(12-18(13-17)26(4,5)6)19(22)21-16-9-7-14(8-10-16)20(23)24/h7-13H,1-6H3,(H,21,22)(H,23,24)
InChI Key:
VVTNSTLJOVCBDL-UHFFFAOYSA-N
SMILES:
O=C(c1cc(cc(c1)[Si](C)(C)C)[Si](C)(C)C)Nc1ccc(cc1)C(=O)O
UNII:
Q1418F39MH
Properties
Complexity:
494
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
385.153g/mol
Formal Charge:
0
Heavy Atom Count:
26
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
385.61g/mol
Monoisotopic Mass:
385.153g/mol
Rotatable Bond Count:
5
Topological Polar Surface Area:
66.4A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Efficient asymmetric reduction of 4-(trimethylsilyl)-3-butyn-2-one by Candida parapsilosis cells in an ionic liquid-containing system. | PloS one 20120101 |
| Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF-mediated signaling. | Journal of neurochemistry 20090701 |
| Chemopreventive effect of 4-[3,5-Bis(trimethylsilyl) benzamido] benzoic acid (TAC-101) on MNU-induced colon carcinogenesis in a rat model. | Anticancer research 20090601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090401 |
| Contribution of AP-1 interference induced by TAC-101 to tumor growth suppression in a hepatocellular carcinoma model. | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20090101 |
| Using a water-immiscible ionic liquid to improve asymmetric reduction of 4-(trimethylsilyl)-3-butyn-2-one catalyzed by immobilized Candida parapsilosis CCTCC M203011 cells. | BMC biotechnology 20090101 |
| A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. | Journal of cancer research and clinical oncology 20081201 |
| A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma. | Gynecologic oncology 20080301 |
| 4- [3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induced fas expression and activated caspase-3 and -8 in a DLD-1 colon cancer cell line. | In vivo (Athens, Greece) 20070101 |
| 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression. | In vivo (Athens, Greece) 20050101 |
| A synthetic retinoid Am80 (tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm. | Biological & pharmaceutical bulletin 20041101 |
| A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma. | Gynecologic oncology 20040901 |
| 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor. | Oncology research 20040101 |
| Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma. | Auris, nasus, larynx 20031201 |
| TAC-101 inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. | Cancer letters 20030820 |
| Effect of synthetic retinoid, TAC-101, on experimental autoimmune disease. | Pharmacology 20030101 |
| Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020815 |
| A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells. | Japanese journal of cancer research : Gann 20011101 |
| TAC-101, a novel retinobenzoic-acid derivative, enhances gap junctional intercellular communication among renal epithelial cells treated with renal carcinogens. | Anticancer research 20010101 |
| The induction of apoptosis and inhibition of AP-1 activity by TAC-101 (4-[3,5-bis(trimethylsilyl) benzamido] benzoic acid) may result in life prolonging effect in animals bearing metastasizing cancer. | Anticancer research 20000101 |
| Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. | International journal of cancer 19990517 |
| 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals. | Clinical & experimental metastasis 19981001 |
| Effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells. | Oncology research 19980101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.